Moreover, molecular and genetic profiling of ultra-rare RPS has revealed some therapeutic targets for subtypes with characteristic driver mutations (e.g., mTOR inhibitors for TSC-mutated PEComa, and Tropomyosin kinase-receptor therapy for NTRK-fusion sarcomas). This evidence concerns the gene MTOR and neoplasm with perivascular epithelioid cell differentiation.